Tel: (615) 20 21 22 23 Background: Current approaches to predicting Cardiovascular disease rely on conventional risk 24 factors and cross-sectional data. In this study, we asked whether: i) machine learning and deep 25 learning models with longitudinal EHR information can improve the prediction of 10-year CVD 26 risk, and ii) incorporating genetic data can add values to predictability. 27 Methods: We conducted two experiments. In the first experiment, we modeled longitudinal 28 EHR data with aggregated features and temporal features. We applied logistic regression (LR), 29 random forests (RF) and gradient boosting trees (GBT) and Convolutional Neural Networks 30 (CNN) and Recurrent Neural Networks, using Long Short-Term Memory (LSTM) units. In the 31 second experiment, we proposed a late-fusion framework to incorporate genetic features. 32 Results: Our study cohort included 109, 490 individuals (9,824 were cases and 99, 666 were 33 controls) from Vanderbilt University Medical Center's (VUMC) de-identified EHRs. American 34 College of Cardiology and the American Heart Association (ACC/AHA) Pooled Cohort Risk 35 Equations had areas under receiver operating characteristic curves (AUROC) of 0.732 and areas 36 under receiver under precision and recall curves (AUPRC) of 0.187. LSTM, CNN and GBT with 37 temporal features achieved best results, which had AUROC of 0.789, 0.790, and 0.791, and 38 AUPRC of 0.282, 0.280 and 0.285, respectively. The late fusion approach achieved a significant 39 improvement for the prediction performance. 40 Conclusions: Machine learning and deep learning with longitudinal features improved the 10-41 year CVD risk prediction. Incorporating genetic features further enhanced 10-year CVD 42 3 prediction performance, underscoring the importance of integrating relevant genetic data 43 whenever available in the context of routine care. 44
ABSTRACT INTRODUCTION
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality, 48 accounting for one-third of all global deaths [1, 2] . There have been several proposed several 49 prediction models, including the Framingham risk score [3] , American College of 50 Cardiology/American Heart Association (ACC/AHA) Pooled Cohort Risk Equations [4] , and 51 QRISK2 [5] . These models are typically built upon a combination of readily-available cross-52 sectional risk factors such as hypertension, diabetes, cholesterol, age, and smoking status. 53
Although the importance of conventional models cannot be ignored, well-known clinical risk 54 factors for CVD explain only 50-75% of the variance in major adverse cardiovascular events [6] . 55 About 15%-20% of patients who experienced myocardial infarctions had only one or two of 56 these traditional risk factors and were not identified as being at "risk" of CVD according to 57 current prediction models [7] . Given the fact that CVD is preventable, and that its first 58 manifestation may be fatal, a new strategy to enhance risk prediction beyond conventional 59 factors is critical for public health. 60
Electronic health records (EHRs) contain a wealth of detailed clinical information and 61 provide several distinct advantages for clinical research, including cost efficiency, a large 62 amount of data, and the ability to analyze data over time. Since its wide implementation in the 63 United States, accumulated EHR data has become an important resource for clinical studies. [8] . 64
Meanwhile, the recent convergence of two rapidly developing technologies-high-throughput 65 genotyping and deep phenotyping within EHRs -presents an unprecedented opportunity to 66 utilize routine healthcare data and genetic information to accelerate the improvement of 67 healthcare. Many institutions and health care systems have been building EHR-linked DNA 68 biobanks to enable such a vision. For example, Vanderbilt University Medical Center (VUMC), 69 as of May 2018, has genotype data of over 50,000 individuals available for research. 70
Machine learning and deep learning approaches are particularly suited to the integration 71 of big data, such as the data available within EHRs, especially when the EHR contains genetic 72 information [9, 10] . A recent study from the United Kingdom (UK) applied machine learning on 73 conventional CVD risk factors from a large UK population and improved the overall prediction 74 performance by 4.9% [11] . In the current study, we examined: i) the performance of machine 75 learning and deep learning on longitudinal EHR data for the prediction of 10-year CVD risk, and 76 ii) the benefits of incorporating extra genetic information. 77
METHODS

78
Study setting 79 We conducted the study using data derived from Synthetic Derivative, a de-identified 80 copy of whole EHRs at VUMC. Synthetic Derivative maintains rich and longitudinal EHR data 81 from over 3 million unique individuals, including demographic details, physical measurements, 82 history of diagnosis, prescription drugs, and laboratory test results. As of May 2018, over 50,000 83 of these individuals have genotype data available. 84
We focused our analysis on individuals with European or African ancestry. We required 85 individuals to meet the definitions of medical home [12] . We set the baseline date as 01/01/2007 86 to allow all individuals within the cohort to be followed-up for 10 years. For each individual, we 87 split the EHR into: i) the observation window (01/01/2000 to 12/31/2006; 7 years) and, ii) the 88 prediction window (01/01/2007 to 12/31/2016; 10 years). We extracted EHR data within the 7-89
year observation window to train a predictive model to predict CVD event occurred in prediction 90 We represented a physical measurement or laboratory feature with summarized data, e.g. 118 minimum, maximum, median, and standard deviation (SD). We removed the outliers (>5 SD 119 from the mean) to avoid unintended incorrect measurements (e.g. using lb. instead of kg. for 120 body weight) [16] . If an individual had no such measure available within the EHR, we imputed 121 the missing value with the median value of the group with the same age and gender [17] . We 122 also added a dummy variable for each measure to indicate whether the test value was imputed. 123
For disease phenotypes, we followed a standard approach and grouped relevant ICD 124 codes into distinct phecodes [19] . For medications, we collapsed brand names and generic names 125 into groups by their composition (ingredients) and represented the groups using the RxNorm [19] 126 concepts (RxCUIs) for this variable. For example, 'Tylenol Caplet, 325 mg oral tablet' and 127 'Tylenol Caplet, 500 mg oral tablet' were both mapped to 'Acetaminophen' (RxCUI 161). We 128 used a binary value to indicate whether or not an individual had each diagnosis or prescription. 129
For genetic data, we selected 248 single nucleotide polymorphisms (SNPs) that have 130 been previously reported to be associated with CVD in two large meta-analyses [20,21]. Among 131 these SNPs, genotype data were available for 204 SNPs in our cohort and were included as 132 features. Each SNP had a value 0, 1, or 2 based on the count of minor alleles for an individual. 133 Table 1 shows the features that we used in the machine learning models. 134 The objective of this experiment is to examine 1) predictive performance achieved by 144 machine learning and deep learning with longitudinal EHR data compared to golds standard, and 145 2) two different approaches we use to model the longitudinal EHR data for machine learning 146 models ( Figure 1 Evaluation. We divided the dataset into a training and a test set with a 90/10 split and 169 learned the models with a 10-fold stratified cross-validation using grid search on the training set. 170
Finally, we evaluated the optimized model on the test set using area under a receiver operating 171 characteristic curve (AUROC) and average precision, also known as area under precision-recall 172 curve (AUPRC) [25] . For each machine learning model, we repeated the above processed 10 173 times. For deep learning models, we randomly divided the data into training, validation, and 174 testing sets with a ratio of 8:1:1 and iterated the process for 10 times. We reported the mean and 175 SD of AUROC and AUPRC. 176
Machine learning and deep learning with additional genetic information to 177 predict 10-year CVD risk. (Experiment II) 178
The objective of this experiment is to examine combining genetic features with 179 demographic and longitudinal EHR data compared to only using demographic and longitudinal 180 EHR data for 10-year CVD prediction. To meet the objectives, we used a subset of 10,162 had 181 genotyped data from the main study cohort of 109, 490 individuals. It is also a subset of BioVU 182 (VUMC's de-identified DNA biobank) that contains nearly >50,000 genotyped individuals. 183
We developed a two-stage framework of using late-fusion approach to incorporate EHR 184 and genotyped features. Late-fusion is an effective approach to enhance prediction accuracy by 185 combining the prediction results of multiple models trained separately by a group of features.
[26] 186
Here, we trained two machine learning models separately by EHR data and genotyped data and 187 used a subset of 10,162 which had both available EHR and genotyped data to train and test a 188 fusion model based on the prediction results. (Figure 2 In the second stage, we combined the predictions scores of two models on the training set (8, 129 199 individuals) to train a late fusion model. We used gradient boosting trees for the model 1 because 200 it has good generalizability as an ensemble approach to make it more robust. We used the 201 logistic regression as model 2 and the late fusion model. 202
To compare the performance of adding genetic features, we evaluated prediction 203 performance of model 1 and fusion model on the holdout test set (2,033 individuals). We 204 performed 5-fold cross-validation and repeated the process 10 times. We reported the mean and 205 SD of AUROC and AUPRC. 206 Feature importance. We listed top features for each of optimized machine learning 229 models in Table 3 . Feature importance was determined by the coefficient effect size from the LR 230 model. For RF and GBT, which are based on decision-trees, the features are ranked according to 231 the impurity (information gain/entropy) decreasing from each feature. Since CNN and LSTM are 232 black box models, estimation of each feature's contribution to predict CVD risk is difficult, so 233
RESULTS
207
Machine learning and deep learning models with longitudinal EHR data to
we were not able to analyze the feature importance of the deep learning models in this study. 234 The conventional risk factors such as age, blood pressure and total cholesterol were 1 consistently present as top 10 features in all three machine learning models. BMI, Creatinine 2 and Glucose that were not in ACC/AHA equations were determined as important features in 3 machine learning models. Moreover, the maximum, minimum, and SD of laboratory values 4 showed promising contributions to the models. GBT models preferred diagnoses such as heart 5 valve disorder, hypertension, and lipid disorders over other features. We listed the top ten features in the pre-trained model with genetic data in Supplementary 21
Appendices S3. SNP (rs2789422) was ranked as the second most important feature after age. 22
DISCUSSION
23
Our results demonstrate that machine learning models with longitudinal EHR information 24 can improve the prediction of 10-year CVD risk. We also showed that incorporating genetic data 25 can enhance 10-year CVD risk prediction. 26
We used a large dataset including longitudinal EHR information of 109, 490 individuals. 27
The prediction result of ACC/AHA (AUROC of 0.732, AUPRC of 0.187) was consistent with 28 previous studies (AUROC of 0.728 in a study conducted in the UK) [11] . 29
For machine learning models with aggregate values, as we used summarized data for 30 physical and laboratory features, and we also included 40 additional pre-selected features 31
including diagnosis codes and medication codes, the performance of prediction was significantly 32 improved. Further, the min, max and SD values were ranked higher in importance than the 33 median values. BMI, medications (e.g. aspirin) that were not used by the ACC/AHA equations 34 were also present in the top 10 features. 35
Longitudinal information reflects the fluctuation of physiological factors over time, 36 which can be used for prediction models to enhance CVD risk prediction. The most recent results 37 from the STABILITY trial suggested the higher visit-to-visit variabilities of both systolic and 38 diastolic blood pressures are strong predictors of increased risk of CVD, independently of mean 39 blood pressure [28] . By zooming in the observation window of one-year slice time, we 40 constructed multivariate temporal features for machine learning models and deep learning 41 models. The results showed that it improved the prediction performance. CNN and LSTM that 42 allows for exhibiting dynamic temporal changes, outperformed LR and RF models. Surprisingly, 43
GBT almost had similar performance as LSTM and CNN. The time steps (7 years, 7-time steps) 44 may not be long enough to activate the gates of LSTM. Another reason is that a 10-year follow-45 up prediction window may be a little long thereby removing the advantage of LSTM and CNN in 46 capturing the dependency with the observation and prediction. 47
Our approach also underscores the importance of including genetic variants. It has long 48 been known that CVD has a sizeable hereditary component [3] , and emerging data continue to 49 increase our understanding of the genetic architecture underlying this important clinical trait 50 [20, 21] . Previous studies have uncovered many novel genetic associations with CVD for risk 51 factors that are also heritable such as lipids, blood pressure, and diabetes [29, 30] . While 52 polygenic scores have been used to summarize genetic effects for diseases, strategies to combine 53 genetic variants with other biological and lifestyle factors for existing predictive models remains 54 a topic of intense ongoing investigation. Although 10,162 individuals (2,452 cases and 7,710 55 controls) of our main study cohort had genotype data available, this subset may still limit our 56 power for large scale genetic analyses and machine learning. Since the quality of prediction often 57 depends on the amount of available training data, without sufficient training data, the learning 58 models cannot differentiate useful patterns from noise and predictive accuracy may 59 underperform. To overcome this challenge, we proposed a late-fusion approach to pre-train the 60 models with EHR features and genetic features separately by taking advantage of a larger 61 genotyped cohort (34,926). 62
From the results, we can see that adding genetic features offered benefit to clinical 63 features and significantly improved the performance compared to gold standard and only using 64 longitudinal EHR features. 65
Importance of Genetic Features
66
We present the top 10 features identified from the cohort (Supplementary Appendices S3). 67
Age remains the strongest predictor for CVD (coefficient 0.747), followed by gender, EHR 68 length and two variants from MIA3 gene. Although dyslipidemia is one of the most important 69 risk factors for CVD, none of the top genes was strong predictor for circulating lipid levels, 70 except LPA gene. 71
While LPA genotype are associated with circulating lipid levels, it also strongly 72 influenced Lp(a) levels which was an independent CVD predictor with or without statin 73 treatment [31] . For decades, lipid-lowering medications (especially statins) have been shown to 74 be effective in both primary and secondary CVD prevention. Our observations highlight the 75 importance of CVD risk determinants independent of lipid levels. These findings underscore the 76 importance of targeting residual CVD risk through non-lipid mechanisms. 77
We acknowledge the limitations that, 1) we manually abstracted a subset of the physical 78 or laboratory features known to impact CVD risk, and we planned to incorporate more laboratory 79 features that could be automatically selected by feature engineering from the EHR, and 2) we 80 only used 204 SNPs in our study, whereas some of effects of the SNPs are modeled by 81 phenotypes (e.g., a SNPs affecting cholesterol are better captured by direct cholesterol 82 measurements). Yet some SNPs for endophenotypes are more predictive of CVD events than the 83 endophenoytpe itself [31] . As each SNP has a relatively small effect size compared with other 84 features like age, gender, and diabetes, and thus may not contribute much to the predictive ability 85 of the models, we believe that with more phenotypic and genetic information available in larger 86 cohorts may further improve prediction. This study confirmed that combining phenotypic and 87 genetic information with robust computational models can improve disease prediction. 88 
